Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 11/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 4/20 | 0.33 |
| ▸ | GHSR | Q92847 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL715806 | 1.00 | OPRK1 (0.36) | OPRK1HRH4ACACBGHSRROCK2 | |
| SCHEMBL715924 | 0.84 | OPRK1 (0.41) | OPRK1ACACB | |
| SCHEMBL17530842 | 0.83 | OPRK1 (0.38) | OPRK1HRH4GHSR | |
| SCHEMBL17530843 | 0.83 | OPRK1 (0.38) | OPRK1HRH4GHSR | |
| SCHEMBL14481792 | 0.81 | OPRK1 (0.39) | OPRK1 | |
| SCHEMBL715385 | 0.80 | OPRK1 (0.43) | OPRK1 | |
| SCHEMBL714751 | 0.80 | DYRK3 (0.46) | OPRK1ACACB | |
| SCHEMBL714750 | 0.80 | DYRK3 (0.46) | OPRK1ACACB | |
| SCHEMBL717165 | 0.80 | OPRK1 (0.36) | OPRK1 | |
| SCHEMBL5299 | 0.80 | SOS1 (0.38) | OPRK1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785628-B2 | Triazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-07-22 | — | — | US | disclosed |
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | MAP3K15, PI4KA, MAP3K20 | OPRK1 416/4885HRH4 1307/4885ACACB 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.